Antiphospholipid syndrome: Multiple mechanisms

Clinical and Experimental Immunology

Volumn 136, Issue 3, 2004, Pages 393-401

  Mackworth Young, C G ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibody; Beta 2 glycoprotein I; Lupus anticoagulant haemostasis; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; APOLIPOPROTEIN A1; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; CARDIOLIPIN; CYCLIC AMP; FATTY ACID BINDING PROTEIN; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; KALLIKREIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; THROMBOXANE; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BLOOD CLOTTING; CELL MEMBRANE; CLINICAL FEATURE; ENDOTHELIUM CELL; FETUS WASTAGE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MONOCYTE; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STROKE; THROMBOCYTE; THROMBOEMBOLISM; THROMBOSIS; VASCULAR DISEASE;

ABORTION, SPONTANEOUS; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; ARTERIOSCLEROSIS; BETA 2-GLYCOPROTEIN I; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOPROTEINS; HEMOSTASIS; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; PREGNANCY; PROTEIN C; THROMBOSIS;

EID: 2542554965     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02497.x     Document Type: Review

References (136)

1. Harris EN, Gharavi AE, Boey ML et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii:1211-4.
2. Alarcon-Segovia D, Deleze M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68:353-65.
3. Cuadrado MJ, Hughes GRV Hughes (antiphospholipid) syndrome, clinical features. Rheum Dis Clin North Am 2001; 27:507-24.
4. Lockshin MD, Druzin ML, Goei S et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Eng J Med 1985; 313:152-6.
5. Laurell B-B, Nilsson IM. Hypergammaglobulinaemia, circulating anticoagulant, and biologic false positive Wassermann reaction. J Laboratory Clin Med 1957; 49:694-707.
6. Bowie EJW, Thompson JH Jr, Pascuzzi CA, Owen CA Jr. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Laboratory Clin Med 1963; 62:416-30.
7. Firkin BG, Howard MA, Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet 1980; ii:366.
8. Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJW. Lupus anticoagulants, an analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19:265-75.
9. Loizou S, McCrea JD, Rudge AC et al. Measurement of anticardiolipin antibodies by enzyme linked immunosorbent assay: standardisation and quantitation of results. Clin Exp Immunol 1985; 62:738-44.
10. Navarrete MG, Brey RL, Levine SR. Cerebral disease in the antiphospholipid syndrome. In: Khamashta MA, ed. Hughes Syndrome, Antiphospholipid Syndrome. London: Springer Verlag 2000:43-58.
11. Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36:970-82.
12. Cuadrado MJ, Mujic F, Munoz E et al. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997; 56:194-6.
13. Mackworth-Young CG, David J, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1987; 26:94.
14. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 42:1309-11.
15. Asherson RA, Khamashta MA, Ordi-Ros J et al. The 'primary' antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68:366-74.
16. Branch DW, Dudley DJ, Mitchell MD et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163:210-6.
17. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome by passive transfer of anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88:3069-73.
18. Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci USA 1993; 90:6464-7.
19. Mason AN, Mageed RA, Mackworth-Young CG. The effects of a human IgM monoclonal anticardiolipin antibody on pregnancy in a transgenic mouse model. Lupus 2001; 10:289-94.
20. Silver RM, Smith LA, Edwin SS e al. Variable effects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies. Am J Obstet Gynecol 1997; 177:229-33.
21. Bakimer R, Fishman P, Blank M et al. Induction of primary antiphospholipid syndrome in mice by immunisation with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89:1558-63.
22. Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994; 3:247-51.
23. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335:1544-7.
24. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4.
25. Roubey RAS. Immunology of the antiphospholipid syndrome. Arthritis Rheum 1996; 39:1444-54.
26. Giles IP, Isenberg DA, Latchman DS, Rahman A. How do antiphospholipid antibodies bind β2-glycoprotein I? Arthritis Rheum 2003; 48:2111-21.
27. Hunt JE, McNeil HP, Morgan GJ et al. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmue disease but not with infection. Lupus 1992; 1:75-81.
28. Forastiero RR, Martinuzzo ME, Kordich LC et al. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thrombosis Haemostasis 1996;75:717-20.
29. Gharavi AE, Sammaritano LR, Wen J et al. Characteristics of HIV and chlorpromazine induced antiphospholipid antibodies: effect of β2-glycoprotein I on binding to phospholipid. J Rheumatol 1984; 21:94-9.
30. Ousting JD, Derksen RH, Bobbink IW et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S. an explanation for their pathogenic mechanism? Blood 1993; 81:2618-25.
31. Lieby P, Soley A, Levallois H et al. The clonal analysis of anticardiolipin antibodies in a single patient with primary antiphospholipid syndrome reveals an extreme antibody heterogeneity. Blood 2001; 97:3820-8.
32. Shoenfeld Y, Krause I, Kvapil F et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid sydrome. J Clin Immunol 2003; 23:377-83.
33. Lee SL, Saunders M, Kahny HMA. A disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest 1955; 34:1814-22.
34. Derksen RH, Hasselar P, Blokzijl L et al. Coagulation screen is more specific than the anticardiolipin aantibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1998; 47:364-71.
35. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgGs (LA) are not directed to phosholipids only, but to a complex of lipid-bound human prothrombin. Thrombosis Haemostasis 1991; 66:629-32.
36. Skjonsberg OH, Wisloff F, Godal HC. Inhibition of the tissue factor-factor VII mediated activation of coagulation factor X by a monoclonal antibody expressing lupus anticoagulant activity. Thrombosis Res 1990; 58:349-52.
37. Bidot O, Horstman LL, Huisheng H et al. Factor VII/VIIa: a new antigen in the antiphospholipid antibody syndrome. Br J Haematol 2003; 120:618-26.
38. Angles-Cano E, Guillin M-C. Antiphospholipid antibodies and the coagulation cascade. Rheum Dis Clin North Am 2001; 27:573-86.
39. Sanfelippo MJ, Drayna CJ. Prekallikrein inhibition assocoated with the lupus anticoagulant. Am J Clin Pathol 1982; 77:275-9.
40. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153:1328-32.
41. Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Up.-regulated tissue factor expression in antiphospholipid syndrome. Thrombosis Haemostasis 1997; 77:222-3.
42. Amengual O, Atsuni T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombosis Haemostasis 1998; 79:276-81.
43. Conti F, Sorice M, Circella A et al. Beta-2-glycoprotein I expression on monocytes is increased in antiphospholipid antibody syndrome and correlates with tissue factor expression. Clin Exp Immunol 2003; 132:509-16.
44. Amengual O, Atsumi T, Koike T. Specificities, properties and clinical significance of antiprothrombin antibodies Arthritis Rheum. 2003; 48:886-95.
45. Sorice M, Pittone V, Circella A et al. Anti-thrombin but not 'pure' anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome. Thrombosis Haemostasis 1998; 80:16-22.
46. Nojima J, Kuratsune H, Suehisa E et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Heamatol 2001; 114:647-54.
47. Nojima J, Kuratsune H, Suehisa E et al. Acquired protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118:577-83.
48. Pengo V, Biasiolo A, Brocco T et al. Autoantibodies to phospholipid-binding proteins in patients with thrombosis and phospholipid-reactive antibodies. Thrombosis Haemostasis 1996; 75:721-4.
49. Forastiero R, Martinuzzo M, Cerrato G et al. Relationship of anti-beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thrombosis Haemostasis 1997; 78:1008-114.
50. Horbach D, van Oort E, Derksen R, de Groot P. The contribution of anti-prothrombin antibodies to lupus anticoagulant activity - discrimination between functional and non-functional anti-prothrombin antibodies. Thrombosis Haemostasis 1998; 79:790-5.
51. Galli M, Beretta G, Daldossi M et al. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thrombosis Haemostasis 1997; 77:486-91.
52. Horbach D, van Oort E, Donders R et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thrombosis Haemostasis 1996; 76:916-24.
53. Atsumi T, Ieko M, Bertolaccini ML et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000; 43:1982-93.
54. Hwang K-K, Grossman JM, Visvanathan S et al. Identification of antithrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167:7192-8.
55. Shibata S, Harpel PC, Gharavi AE et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83:2532-40.
56. Gonias SI, Pizzo SV. The biochemistry of haemostasis. Clin Laboratory Haematol 1986; 8:281-305.
57. Marciniak E, Romond EH. Impaired catalytic function of activated protein C. a new manifestation of lupus anticoagulant. Blood 1989; 74:2426-32.
58. Borrell EM, Sala N, de Castellarnau C et al. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thrombosis Haemostasis 1992; 68:268-72.
59. Smirnov MD, Triplett DT, Comp PC et al. On the role of phosphtidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95:309-16.
60. Malia RG, Kirchens S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76:101-7.
61. Comp PC, DeBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62:299a.
62. Freyssinet JM, Wiesel M-L, Gauchy J et al. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis. Thrombosis Haemostasis 1986; 55:309-13.
63. Sakata Y, Curriden S, Lawrence D et al. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases anti-activator activity. Proc Natl Acad Sci USA 1985; 82:1121-5.
64. Van Hinsberg VWM, Bertina RM, van Wijngaarden A et al. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1986; 65:444-51.
65. Violi F, Ferro D, Valesini G et al. Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. Br Med J 1990; 309:1099-102.
66. Keeling DM, Campbell SJ, Mackie IJ et al. The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. Br J Haematol 1991; 77:354-9.
67. Cugno M, Cabibbe M, Galli M et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in two patients. Blood 2004; 00:000-000. in press
68. Mackworth-Young CG, Andreotti F, Harmer IJ et al. Endothelium-derived haemostatic factors and the antiphospholipid syndrome. Br J Rheumatol 1995; 34:201-6.
69. Andree HA, Stuart MC, Hermens WT et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267:17907-12.
70. Matsuda J, Saitoh N, Gohchi K et al. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994; 47:56-8.
71. Rand JH, Wu XX, Quinn AS et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163:1193-200.
72. Arai T, Matsubayashi H, Sugi T et al. Anti-annexin A5 antibodies in reproductive failures in relation to antiphospholipid antibodies and phosphatidylserine. Am J Reprod Immunol 2003; 50:202-8.
73. Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex Blood. 1995; 86:3083-9.
74. Merten M, Motamedy S, Ramamurthy S et al. Sulfatides: targets for anti-phospholipid antibodies. Circulation 2003; 108:2082-7.
75. Forastiero RR, Martinuzzo ME, Lu L, Broze GJ. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thrombosis Haemostasis 2003; 1:1764-70.
76. Joseph JE, Harrison P, Mackie IJ et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115:451-9.
77. Reverter JC, Tassies D, Font J et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41:1420-7.
78. Font J, Esinosa G, Tassies D et al. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. Arthritis Rheum 2002; 46:3283-9.
79. Robbins DL, Leung S, Miller-Blair DJ et al. Effect of anticardiolipin/ beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with antiphospholipid syndrome. J Rheumatol 1998; 25:51-6.
80. Opara R, Robbins DL, Ziboh VA, Cyclic AMP agonists inhibit antiphospholipid/beta2-glycoprotein I induced synthesis of human platelet thromboxane A2 in vitro. J Rheumatol 2003; 30:55-9.
81. Lutters BCH, Derksen RHWM, Tekelenburg WL et al. Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278:33831-8.
82. Reverter JC, Tassies D. Mechanisms of thrombosis in the antiphospholipid syndrome: binding to platelets. In: Hughes Syndrome, Antiphospholipid Syndrome. Khamashta, MA, ed. Springer Verlag, 2000:pp 290-8.
83. Galli M, Daldossi M, Barbui T. Anti-glycoprotein IIb/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thrombosis Haemostasis 1994; 71:571-5.
84. Godeau B, Piette J-C, Fromont P et al. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997; 98:873-9.
85. Carreras LO, Defreyn G, Machin SJ et al. Arterial thrombosis, intrauterine death and 'lupus' anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; i:244-6.
86. Rustin MHA, Bull HA, Machin SJ et al. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus in endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 1988; 90:744-8.
87. Coade SB, van Haaren E, Loizou S et al. Endothelial prostacyclin relaese in systemic lupus erythematosus. Thrombosis Haemostasis 1989; 61:97-100.
88. Riboldi P, Gerosa M, Raschi E et al. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003; 207:29-36.
89. Rosenbaum J, Pottinger BE, Woo P et al. Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988; 72:450-6.
90. Vismara A, Meroni PL, Tincani A et al. Relationship between anticardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 1988; 74:247-53.
91. Hassalaar P, Derksen RHWM, Blokzijl L, de Groot PG. Cross reactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thrombosis Haemostasis 1990; 63:169-73.
92. Del Papa N, Guidali L, Spatola L et al. Relationship between antiphospholipid and anti-endothelial cell antibodies III. β2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995; 13:179-85.
93. Simantov R, LaSala JM, Lo SK et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211-9.
94. Gharavi AE, Pierangeli SS, Colden-Stanfield M et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J. Immunol 1999; 163:2922-7.
95. Pierangeli SS, Colden-Stanfield M, Liu JH et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99:1997-2002.
96. George J, Blank Y, Levy P et al. Differential effects of anti-beta 2 glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998; 97:900-6.
97. Meroni PL, Raschi E, Camera M et al. Endothelial activation by aPL. a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15:237-40.
98. Dunoyer-Geindre S, de Moerloose P. Galve-de Rochemonteix B et al. NFκB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein I antibodies. Thrombosis Haemostasis 2002; 88:851-7.
99. Ma K, Simantov R, Jing-Chuan Z et al High affinity binding of β2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275:15541-8.
100. Dobado-Berrios PM, Lopez-Pedrera C, Velasco F et al. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thrombosis Haemostasis 1999; 82:1578-82.
101. Price BE, Jauch J, Shia MA et al. Anti-phospholipid antibodies bind to apoptotic, but not viable, thymocytes in a β2-glycoprotein I-dependent manner. J Immunol 1996; 157:2201-8.
102. Atsumi T, Khamashta MA, Haworth RS et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin I. Arthritis Rheum 1998; 41:800-7.
103. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93:513-9.
104. MacGregor AJ, Dhillon VB, Binder A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rhem Dis 1992; 38:529-34.
105. Matsuura E, Kobayashi K, Kasahara J et al. Anti-β2-glycoprotein I autoantibodies and atherosclerosis. Intern Rev Immunol 2002; 21:51-66.
106. Vaarala O, Alfthan M, Jauhiainen M. et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 2003; 341:923-5.
107. Tinahones FJ, Cuadrado MJ, Khamashta MA et al. Lack of crossreaction between antibodies to β2-glycoprotein I and oxidised low-density lipoprotein in patients with antiphospholipid syndrome. Br J Rheumatol 1998; 37:746-9.
108. Kobayashi K, Matsuura E, Liu Q et al. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidised low density lipoprotein by macrophages. J Lipid Res 2001; 42:697-709.
109. George J, Harats D, Gilburd B et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunised with β2-glycoprotein I. Circulation 1988; 98:1108-15.
110. Ames PRJ. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying 'membrane stress syndrome' hypothesis. Lupus 1994; 3:371-7.
111. Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high-density lipiprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2003; 42:893-9.
112. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: are they proatherogenic or an epiphenomenon of atherosclerosis? Immunobiology 2003; 207:13-6.
113. Mackworth-Young CG, Loizou S, Walport MJ. Antiphospholipid antibodies and disease. Quart J Med 1989; 72:767-77.
114. Stone S, Khamashta MA, Poston L. Placentation, antiphospholipid syndrome and pregnancy outcome. Lupus 2001; 10:67-74.
115. Gharavi AE, Pierangeli SS, Levy RA, Harris EN. Mechanisms of pregnancy loss in antiphospholipid syndrome. Clin Obstet Gynecol 2001; 44:11-9.
116. Parke AL. Placental pathology in antiphospholipid antibody syndrome. In: Khamashta MA, ed. Hughes Syndrome, Antiphospholipid Syndrome. London: Springer Verlag, 2000:281-9.
117. Donohoe S, Kingdom JCP, Mackie IJ. Affinity purified human antiphospholipid antibodies bind normal term placenta. Lupus 1999; 8:525-31.
118. Chamley LW, Duncalf AM, Mitchell MD et al. Action of anticardiolipin and antibodies to beta 2 glycoprotein I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352:1037-8.
119. Di Simone N, Meroni PL, Del Papa N et al. Antiphospholipid antibodies affect trophoblast gonadotrophin secretion and invasiveness by binding directly and through adhered beta 2 glycoprotein I. Arthritis Rheum 2000; 43:140-53.
120. Tartakovski B, Bermas BL, Sthoeger Z et al. Defective maternal-fetal interaction in a murine autoimmune model. Human Reprod 1996; 11:2408-11.
121. Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211-20.
122. Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644-54.
123. Xu C, Mao D, Holers VM et al. A critical role for the murine complement receptor Crry in fetomaternal tolerance. Science 2000; 287:498-501.
124. Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41:179-86.
125. Magid MS, Kaplan C, Sammaritano LR et al. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 1998; 179:226-34.
126. Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischaemia. Clin Exp Immunol 1992; 10:455-60.
127. Munakata Y, Saito T, Seino J et al. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thrombosis Haemostasis 2000; 83:728-31.
128. Levine SR, Brey RL, Tilley BC et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. J Am Med Assoc 2004; 291:576-84.
129. Kent M, Vogt E, Rote NS. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J Rheumatol 1997; 24:1725-33.
130. Caronti B, Calderaro C, Alessandri C et al. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998; 11:425-9.
131. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8:127-33.
132. Shoenfeld Y, Nahum A, Korczyn AD et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003; 12:436-42.
133. Lima F, Khamashta MA, Buchanan NMM et al. A study of sixty pregnancies with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14:131-6.
134. Ringrose DK. Anaesthesia and antiphospholipid syndrome - a review of 20 obstetric patients. Int J Obstet Anaesth 1997; 6:107-11.
135. Brenner B, Vulfons SL, Lanir N, Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis. Br J Haematol 1996; 94:166-7.
136. Rosendaal F. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thrombosis Haemostasis 1997; 78:1-6.